In addition to regulation of normal cell functions, hepatocyte growth factor (HGF) has also been shown to be involved in malignant cell transformation and in growth, invasion and metastasis in cancer cells. Inhibitors of HGF production have a potential for interfering with malignant cell transformation and progression of tumors. We found that tryptanthrin, one of the major compounds extracted from the medicinal plant Polygonum tinctorium, which is known for its antitumor activity, strongly inhibited HGF production stimulated by various HGF inducers in human dermal fibroblasts. HGF production induced by phorbol 12-myristate 13-acetate (PMA) was potently inhibited by tryptanthrin without any appreciable cytotoxic effect. Tryptanthrin also inhibited HGF production induced by epidermal growth factor (EGF) and platelet-derived growth factor. Moreover, proliferation of the fibroblasts induced by the two growth factors was potently suppressed by tryptanthrin to the level of proliferation of unstimulated fibroblasts. However, tryptanthrin did not inhibit HGF production induced by the protein kinase A-activating agents cholera toxin and 8-bromo-cAMP. These effects of tryptanthrin were different from the effects of transforming growth factor b b1 and dexamethasone, both of which inhibit HGF production induced by all the above inducers. Upregulations of HGF gene expression by PMA and EGF were also inhibited by tryptanthrin. Activation of the mitogen-activated protein kinase (MAPK) signaling pathway is crucial for PMAinduced HGF production, but tryptanthrin did not attenuate phosphorylation of MAPK induced by PMA. These results indicate that tryptanthrin potently inhibited induction of HGF production probably through events downstream of MAPK activation.
Hepatocyte growth factor (HGF), also known as scatter factor, was initially isolated as a mitogenic factor for adult rat hepatocytes in primary culture, but HGF has been shown to have multiple activities, including mitogenic, motogenic and morphogenic activities. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] HGF acts on many kinds of cell targets, including epithelium, endothelium, myoblasts, neurons and hematopoietic cells. [13] [14] [15] Based on these actions, HGF has been shown to play an important role in regeneration of various tissues and in embryonic and fetal development. In addition to regulation of normal cell functions, HGF has also been shown to be involved in malignant cell transformation and growth, invasion and metastasis in cancer cells. [16] [17] [18] [19] Point mutations in the gene encoding for the HGF receptor, Met, have been identified in hereditary and sporadic cases of papillary renal carcinoma, sporadic hepatocellular and gastric carcinomas, and head and neck squamous carcinomas. [20] [21] [22] [23] [24] [25] These mutations of met invariably result in increased tyrosine kinase activity and in the acquisition of transforming potential, but this kind of tumorigenesis is dependent on ligand stimulation, suggesting that the onset of these carcinomas is dependent on both the presence of inherited or acquired alterations in Met and the local availability of HGF, its normal ligand. 26) HGF is mainly produced by mesenchymal cells such as fibroblasts and smooth muscle cells and acts on target cells, that express Met, in a paracrine manner. 6) In some cases, tumor cells express both HGF and Met, setting the stage for an autocrine loop in which secreted HGF binds to Met and causes constitutive activation of Met and its downstream signaling pathways, thus enhancing tumor growth and invasive behavior. Such HGF-Met autocrine loops have been detected in gliomas, osteosarcomas, and mammary, prostate, breast, lung, and other carcinomas. 19) HGF is secreted as an inactive single-chain precursor and is extracellularly converted to an active heterodimer form by several proteases, including a serine protease isolated from serum and homologous to coagulation factor XII (HGF activator) and urokinase-type and tissue-type plasminogen activators. [27] [28] [29] [30] Thus, the use of inhibitors of HGF production and/or HGF activation to interfere with malignant cell transformation and the progression of tumors is a crucial issue deserving intense research. We report here that tryptanthrin, which is a naturally occurring substance found in the medicinal plants Polygonum tinctorium and Isatis tinctoria and has been reported to have antitumor activity toward a variety of human leukemia cells and cancer cells, 31, 32) potently inhibited HGF production induced by phorbol 12-myristate 13-acetate (PMA) and growth factors, including epidermal growth factor (EGF), in human dermal fibroblasts.
MATERIALS AND METHODS

Materials
Dulbecco's modification of Eagle's minimum essential medium (DMEM) was purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Tryptanthrin was obtained from Wako Pure Chemical Industries (Osaka, Japan). 8-Bromo-cAMP, cholera toxin, PMA, dexamethasone, alltrans-retinoic acid and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Mouse natural EGF and recombinant human platelet-derived growth factor (PDGF) BB homodimer were obtained from BD Bio-sciences (San Jose, CA, U.S.A.) and Austral Biologicals (San Ramon, CA, U.S.A.), respectively. Recombinant human basic fibroblast growth factor (bFGF) and natural human transforming growth factor b1 (TGF-b1) were obtained from R&D Systems (Minneapolis, MN, U.S.A.). PD 98059 was purchased from Calbiochem (La Jolla, CA, U.S.A.). Rabbit anti-phosphorylated p44/42 mitogen-activated protein kinase (phospho-p44/42 MAPK) antibody and anti-p44 MAPK antibody (K-23) were obtained from Cell Signaling Technology (Beverly, MA, U.S.A.) and Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.), respectively. [a-
32 P]dCTP (ca. 110 TBq/mmol) was purchased from Amersham Biosciences (Little Chalfont, England). Human HGF cDNA (BamHI/KpnI fragment, 2.2 kbp) was derived from plasmids originally obtained from Dr. Naomi Kitamura (Tokyo Institute of Technology, Yokohama, Japan). Other reagents were obtained from the described sources. 33) Cell Culture Normal human dermal fibroblasts isolated from 200 individual neonatal donors (Cell Systems, Kirkland, WA, U.S.A.) were used between 7th and 10th passages. The cells were grown as monolayers in DMEM supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO 2 and 95% air as described previously.
34)
Determination of HGF Levels in Conditioned Media
Human dermal fibroblasts, trypsinized and suspended in the medium described in the previous section, were seeded in 96-well plates (Nunc, Roskilde, Denmark) at a density of 1.8ϫ10 4 cells/cm 2 (0.17 ml/well). After reaching confluence, the medium was replaced with the same fresh medium or that containing tryptanthrin, and the cultures were incubated for 1 h. The HGF inducer PMA, EGF, cholera toxin or 8-bromocAMP was then added. The conditioned medium was collected after incubation of the cells for 24 h (PMA-treated human dermal fibroblasts) or 72 h (EGF-, cholera toxin-or 8-bromo-cAMP-treated human dermal fibroblasts), unless stated otherwise, and was frozen at Ϫ30°C for a human HGF ELISA. The sandwich ELISA for human HGF was performed at room temperature as described previously, 35) with a slight modification, 36) except that biotinylated goat antihuman HGF antibody (R&D Systems, Minneapolis, MN, U.S.A.) and horseradish peroxidase-streptavidin conjugate (Zymed Laboratories, San Francisco, CA, U.S.A.) were used as a detection antibody and a horseradish peroxidase conjugate, respectively. HGF levels were expressed as ng/mg cellular protein. 34) Cellular protein was determined as described previously. 34, 37) MTT Assay The medium of confluent human dermal fibroblasts grown in 96-well plates (Nunc, Roskilde, Denmark) was replaced with the same fresh medium or that containing tryptanthrin, and the cultures were incubated for 1 h. The HGF inducer PMA or EGF was then added, and the cells were incubated for 24 h (PMA-treated cells) or 72 h (EGFtreated cells). The medium was then replaced with 100 ml of the same fresh culture medium, and the cultures were incubated for 1 h. MTT assay was performed as described previously. 38) Briefly, 25 ml of a sterile MTT solution (5 mg/ml) in phosphate-buffered saline was added to the culture. After 60 min of incubation, 100 ml of an extraction buffer (12.8% SDS, 0.27 M acetate buffer, pH 4.5, 32% N,N-dimethylformamide), the pH of which was adjusted to 4.5 with HCl, was added. The plate was sealed, mixed throughly, and further incubated overnight at 37°C. The optical densities at 570 nm were then measured using a plate reader (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
Northern Blot Analysis The medium (15 ml) of confluent human dermal fibroblasts grown in 9-cm dishes (Nunc, Roskilde, Denmark) was replaced with the same fresh medium or that containing tryptanthrin, and the cultures were incubated for 1 h. The HGF inducer PMA, EGF or cholera toxin was then added. After incubating for an appropriate period, total RNA was isolated from the cells using RNA-Bee (TEL-TEST, Friendswood, TX, U.S.A.). Northern blotting was performed as described previously. 33) Briefly, total RNA (10 mg) was denatured with 2.2 M formaldehyde and 50% formamide, mixed with ethidium bromide (50 mg/ml), and fractionated on 1% agarose gels containing 2.2 M formaldehyde. The gel was photographed by ultraviolet illumination. The RNA was then transferred from the gel to a Biodyne nylon membrane. The membrane-bound RNA was hybridized to a 32 P-labeled human HGF cDNA probe. After being washed, the membrane was exposed to an imaging plate at room temperature, and the plate was analyzed using a Bio-imaging analyzer, BAS-1800II (Fuji Photo Film Co., Tokyo, Japan). The signal intensity of the 6.8-kb HGF mRNA band was normalized to the fluorescence intensity of the 28S rRNA band. The human HGF cDNA fragment was labeled with [a-32 P]dCTP by using a megaprime DNA labeling system (Amersham Biosciences, Little Chalfont, England) according to the manufacturer's instructions.
Western Blot Analysis The medium (1 ml) of confluent human dermal fibroblasts grown in 24-well plates (Nunc, Roskilde, Denmark) was replaced with the same fresh medium, and the cells were incubated for 15 h. The cells were then incubated for 1 h with or without tryptanthrin or PD 98059 before adding PMA. After incubating for an appropriate period, cells were washed three times with ice-cold PBS, lysed by adding 30 ml of SDS sample buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% Bromophenol Blue), and scraped. Lysates were boiled for 10 min, briefly sonicated, and centrifuged. Protein in extracts was determined by a modification 39) of the method of Lowry et al. 37) Western blotting was performed as described previously. 40) Briefly, protein aliquots (each 10 mg) were separated by 10% SDS-PAGE and transferred electrophoretically to Immobilon-P transfer membranes (Millipore, Billerica, MA, U.S.A.). The membranes were then probed with anti-phospho-p44/42 MAPK antibody or antip44 MAPK antibody and then incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG (Amersham Biosciences, Little Chalfont, England) and detected with ECL Plus Western blotting detection reagents (Amersham Biosciences, Little Chalfont, England). Densitometric analysis of the bands was performed using a UMAX PowerLook II flat-bed scanner (UMAX Data Systems, Taipei, Taiwan) and Intelligent Quantifier software (Bio Image Systems, Ann Arbor, MI, U.S.A.). The signal intensity of the phosphorylated p44 MAPK and p42 MAPK bands was normalized to that of the total p44 MAPK and p42 MAPK and expressed as fold-change relative to the control cultures, which were incubated in the medium alone. 
RESULTS
Inhibition of PMA-and EGF-Induced HGF Production by Tryptanthrin Human dermal fibroblasts produce a small amount of HGF, but its production is markedly induced by protein kinase C-activating phorbol esters, including PMA, protein kinase A (PKA)-activating agents and growth factors such as EGF, PDGF and bFGF. 33, 34, 41) Human dermal fibroblasts were incubated for 24 h with PMA or for 72 h with EGF in the presence of 0.001-2 mg/ml of tryptanthrin, and the amounts of HGF secreted into the media were measured by an HGF ELISA. Tryptanthrin significantly inhibited HGF production induced by PMA at doses of more than 0.1 mg/ml, 70% inhibition being observed with 0.1 mg/ml of tryptanthrin (Fig. 1A) . The effect of tryptanthrin on basal HGF production in 24-h cultures could hardly be determined because of small amounts of HGF produced. The number of viable cells in the cultures treated with or not treated with PMA was not affected by any dose of tryptanthrin as determined by the MTT method (Fig. 1B) . EGF-induced HGF production and EGF-induced increase in the number of viable cells were inhibited by tryptanthrin at doses of more than 0.01 mg/ml and more than 0.1 mg/ml, respectively (Figs.  2A, B) . At 2 mg/ml, tryptanthrin inhibited EGF-induced HGF production by 70% and almost completely inhibited the EGF-induced increase in the number of viable cells up to the level in cultures treated with tryptanthrin alone. Cell viability, determined by trypan blue-exclusion test, in the cultures treated or unteated with EGF was not decreased by tryptanthrin (data not shown). HGF production and cell proliferation induced by PDGF and bFGF were also inhibited by similar doses of tryptanthrin (data not shown). In contrast, HGF production induced by either the cAMP-elevating agent cholera toxin or the membrane-permeable cAMP analog 8-bromocAMP was not inhibited by 0.001-2 mg/ml of tryptanthrin (data not shown). Figure 3 shows a time-course of the effect of tryptanthrin on PMA-or EGF-induced HGF production. HGF levels secreted from PMA-treated fibroblasts were highest at 24 h and decreased thereafter. In contrast, HGF secretion from EGFtreated cells was minimal at 24 h but became remarkable at 48 and 72 h. The inhibitory activity of tryptanthrin toward PMA-and EGF-induced HGF production was detected as early as 24 h and 48 h, respectively.
Tryptanthrin-Caused Inhibition of HGF Gene Expression Upregulated by PMA and EGF The effect of tryptanthrin on induced HGF gene expression determined 15 or 64 h after the addition of tryptanthrin is shown in Fig. 4 . Tryptanthrin significantly reduced the HGF mRNA levels upregulated by PMA and reduced to a lesser extent those upregulated by EGF. The induced HGF mRNA levels in cholera toxin-treated cells were not decreased by tryptanthrin.
Comparison of the Inhibitory Effects of Tryptanthrin with Those of TGF-b b1 and Dexamethasone TGF-b and glucocorticoids are inhibitors of HGF production in various cells, including human dermal fibroblasts. 34, [42] [43] [44] Retinoic acid inhibits PMA-and EGF-induced HGF production in human dermal fibroblasts, whereas it enhances cholera toxinand 8-bromo-cAMP-induced HGF production.
45) The effect of tryptanthrin on HGF production stimulated by various HGF inducers was compared with effects of TGF-b1, dexamethasone and retinoic acid. The inhibitory effect of tryptanthrin on PMA-induced HGF production was comparable to the effect of retinoic acid but was less potent than the effects of dexamethasone and and TGF-b1 (Fig. 5) . The inhibitory effect of tryptanthrin on EGF-induced HGF production was comparable to the effects of dexamethasone and retinoic acid but was less potent than the effect of TGF-b1 (Fig. 5) . Cholera toxin-induced HGF production was strongly inhibited by TGF-b1 and dexamethasone, while the induction was enhanced by retinoic acid and was unaffected by tryptanthrin as described above (Fig. 5) .
Effects of Tryptanthrin on PMA-Induced Phosphorylation of MAPK PMA-induced HGF production was reported to be potently inhibited by PD 98059, a specific MEK inhibitor, indicating that activation of the MAPK signaling Confluent human dermal fibroblasts were pre-incubated for 1 h with or without 0.1 mg/ml of tryptanthrin. The cells were then incubated for 15 h with or without 3 nM PMA or for 64 h with or without 3 ng/ml of EGF or 1 pM cholera toxin in the prersence or absence of tryptanthrin. Total RNA was isolated and Northern-blotted using the 32 Plabeled cDNA probe for human HGF. Autoradiographs and fluorescence photographs (A) are representative of three-five independent experiments. The data (B) are expressed as percent of HGF mRNA levels in the cultures incubated with the inducer alone and are means of three-five independent experiments. Bars indicates S.E.M. HGF mRNA levels in cultures with PMA, EGF and cholera toxin alone were 8.1Ϯ2.4-, 2.5Ϯ0.3-and 6.6Ϯ1.1-times higher, respectively, than that in the control culture, which was incubated in the medium alone. Values that are significantly different from those of the respective controls (inducer alone) are indicated by * pϽ0.05, * * pϽ0.01 (Student's t-test or Welch's t-test).
pathway is crucial for HGF production stimulated by PMA. 40) To elucidate the mechanism underlying tryptanthrincaused inhibition of HGF induction, the effect of tryptanthrin on PMA-induced phosphorylation of MAPK was examined. PMA-induced upregulation of MAPK phosphorylation in human dermal fibroblasts peaked at 15 min of incubation (data not shown). Tryptanthrin did not show any significant effect on MAPK phosphorylation in cells treated with PMA, whereas both tryptanthrin and PD 98059 potently inhibited PMA-induced HGF production, and the latter strongly suppressed PMA-induced MAPK phosphorylation (Fig. 6 ).
DISCUSSION
It has been reported that fibroblasts or paracrine factors produced by fibroblasts are important in the regulation of cancer cell behavior such as proliferation, invasion and metastasis. [46] [47] [48] Hepatocyte growth factor, a growth factor produced by fibroblasts, has been shown to be involved in tumor growth and invasion. [16] [17] [18] [19] Thus, downregulation of HGF expression may decrease ligand-dependent transformation, growth, invasion and metastasis of Met-expressing cancer cells caused in a paracrine manner. We have demonstrated in this study that tryptanthrin potently inhibited HGF production induced by PMA, a protein kinase C activator, and EGF in human dermal fibroblasts. Since HGF production induced by cholera toxin-or 8-bromo-cAMP was not affected by tryptanthrin, the inhibition was specific to PMAand EGF-induced HGF production. The inhibition is not due to a cytotoxic effect, because tryptanthrin did not decrease the number of viable cells cultured with or without PMA. The number of viable cells in EGF-treated cultures, however, was dose-dependently decreased by tryptanthrin to the level of control cultures not treated with EGF, indicating that tryptanthrin completely inhibited the proliferation induced by EGF without any appreciable effect on cell viability. Proliferation of human dermal fibroblasts induced by the other growth factors PDGF and bFGF was also attenuated by tryptanthrin. Thus, tryptanthrin is a potential anti-tumor agent having both an anti-proliferative activity toward various growth factors and an activity for inhibiting HGF production.
Although under physiological conditions, HGF is mainly produced by stromal cells and acts on Met-expressing target cells in a paracrine manner, in some cases, tumor cells express both HGF and Met. Such HGF-Met autocrine loops have been detected in gliomas, osteosarcomas, and mammary breast and other carcinomas. 19) Interference with either HGF or Met expression in human tumor cells decreases their tumorigenic potential. 49) Like other tumor cells, glioma, osteosarcoma and breast cancer cells often produce autocrine growth factors such as PDGF, TGF-a, EGF and bFGF [50] [51] [52] [53] that can induce HGF expression. 41) Since tryptanthrin attenuated HGF production induced by EGF and other growth factors, HGF production in such tumor cells could be effectively inhibited by tryptanthrin.
The precise nature of a target involved in tryptanthrincaused inhibition of HGF induction remains to be elucidated. Tryptanthrin may cause the inhibition through a mechanism distinct from those by which TGF-b and dexamethasone act, because the latter two block HGF production induced by PKA-activating agents as well as that induced by PMA and EGF. 33, 34, 41) Little is known about the mechanisms responsible for TGF-b-and dexamethasone-caused inhibition of HGF induction, but it has been suggested that TGF-b increases the rate of HGF mRNA degradation. 54) Since PMAinduced HGF production is potently inhibited by the specific MEK inhibitor PD 98059, activation of the MAPK signaling pathway is crucial for HGF induction caused by PMA. 40) Tryptanthrin, however, did not downregulate PMA-induced phosphorylation of MAPK. Therefore, a target of tryptanthrin might exist in the PMA signaling pathways downstream to phosphorylation of MAPK. However, this does not rule out the possibility that tryptanthrin indirectly acts on the PMA signaling pathways downstream to phosphorylation of MAPK via its primary target in another signaling pathway. The effect of tryptanthrin on HGF induction resembles that of retinoic acid: both potently inhibited PMA-and EGF-in- Confluent human dermal fibroblasts were pre-incubated for 1 h with or without tryptanthrin (0.1 mg/ml), retinoic acid (10 mM for PMA-and EGF-induced HGF production orduced HGF production, although retinoic acid but not tryptanthrin enhanced HGF production induced by cholera toxin (Fig. 5 ). This similarity is worthy of further study because retinoic acid and the aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin have been shown to elicit a number of common biochemical and toxic responses, including teratogenic effects in mice and inhibition of cell proliferation of various cell lines, 55) and some tryptanthrin derivatives biosynthesized in incubations of Candida lipolytica with tryptophan and anthranilic acid or its derivatives have been reported to activate the aryl hydrocarbon receptor. 56) Other studies have demonstrated that tryptanthrin inhibits the production of interferon g and interleukin 2 by mouse spleen cells and Peyer's patch lymphocytes in culture at concentrations comparable to those for inhibition of HGF induction, 57) but the cellular signaling pathway involved in tryptanthrin-mediated inhibition of production of these cytokines remains unknown. It is possible that determination of the exact target for tryptanthrin in attenuating HGF induction may enable the molecular mechanism underlying tryptanthrin-mediated inhibition of production of interferon g and interleukin 2 to be elucidated.
In conclusion, this study demonstrated that tryptanthrin potently inhibited PMA-, EGF-, PDGF-and bFGF-induced HGF production and EGF-, PDGF-and bFGF-induced cell proliferation without any appreciable cytotoxic effect. The fact that there was no inhibitory effect of tryptanthrin on MAPK phosphorylation upregulated by PMA suggests that tryptanthrin inhibited HGF induction through events downstream of MAPK activation. 
